Status:
UNKNOWN
Radiofrequency Ablation With Gradual Radiofrequency Energy Increment for Hepatocellular Carcinoma Treatment
Lead Sponsor:
Seoul National University Hospital
Collaborating Sponsors:
Starmed
Conditions:
Hepatocellular Carcinoma
Liver Cirrhosis
Eligibility:
All Genders
20-85 years
Phase:
NA
Brief Summary
To evaluate local tumor progression rate at 12 months after percutaneous radiofrequency ablation with gradual radiofrequency energy delivery mode with Octopus electrodes in patients with hepatocellula...
Eligibility Criteria
Inclusion
- Child-Pugh Class A or B
- chronic hepatitis B or liver cirrhosis
- contrast enhanced computed tomography (CT) or magnetic resonance imaging (MRI) within 60 days of scheduled radiofrequency ablation (RFA) date
- clinically diagnosed hepatocellular carcinoma (HCC), equal or less than 4 cm
Exclusion
- number of HCC, equal or more than 3
- largest tumor size over 4 cm
- Child-Pugh class C
- presence of vascular invasion by HCC
- platelet count less than 40,000 per mm3 or International Normalized Ratio (INR) prolongation over 50%
- presence of extrahepatic metastasis
Key Trial Info
Start Date :
January 6 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 30 2023
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05397860
Start Date
January 6 2020
End Date
August 30 2023
Last Update
June 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea